- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05358379
A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.
Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:
Group 1: Bladder cancer
Group 2: Breast cancer: Triple-negative breast cancer (TNBC)
Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])
Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)
Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC
Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)
Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])
Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Mark H Kirschbaum, MD
- Numéro de téléphone: 626-316-3394
- E-mail: mark.kirschbaum@tethrabio.com
Sauvegarde des contacts de l'étude
- Nom: Jason Summa
- E-mail: jason.summa@tethrabio.com
Lieux d'étude
-
-
-
Seoul, Corée du Sud
- Pas encore de recrutement
- Seoul National University Hospital
-
Contact:
- Do-Youn Oh, Prof. MD
- Numéro de téléphone: +82-2-2072-0701
- E-mail: ohdoyoun@snu.ac.kr
-
-
-
-
-
Barcelona, Espagne
- Pas encore de recrutement
- Hospital Universitario Vall d'Hebron
-
Contact:
- Maria Vieito, MD
- E-mail: Mvieito@vhio.net
-
-
-
-
New York
-
New York, New York, États-Unis, 10065
- Recrutement
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
Contact:
- Horwitz Steven, MD
- Numéro de téléphone: +1 646-608-2680
- E-mail: Horwitzs@mskcc.org
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- MD Anderson Cancer Center
-
Contact:
- Rabia Khan
- Numéro de téléphone: +1 713-563-4667
- E-mail: RKhan@mdanderson.org
-
-
Washington
-
Seattle, Washington, États-Unis, 98109
- Recrutement
- Fred Hutchinson Cancer Center/ University of Washington
-
Contact:
- Gentry GT King, MD
- E-mail: gking@fredhutch.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Males or females aged ≥ 18 years.
-
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
- For Phase 1, all tumor types may be enrolled
- For Phase 2, subjects will be enrolled as per the study design section above
-
ECOG performance status of 0-2.
-
Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
-
Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
-
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
-
Able to agree to and sign the informed consent and to comply with the protocol.
Exclusion Criteria:
-
Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
-
Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.
-
Subjects with a history of another primary malignancy, other than:
- In situ carcinomas, e.g., breast, cervix, and prostate
- Locally excised nonmelanoma skin cancer
- No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
-
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
-
Diseases that significantly affect GI absorption of THT140.
-
Subjects who have impaired cardiac function or clinically significant cardiac disease.
-
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
-
Presence of an active infection requiring intravenous antibiotics
-
Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
-
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
-
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Phase 1 Dose Escalation
Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Autres noms:
|
|
Expérimental: Phase 2
Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Maximum tolerated dose
Délai: 6 months
|
The incidence rate of dose-limiting toxicities (first cycle only) at each dose level |
6 months
|
|
Overall Response Rate (ORR)
Délai: 18 months
|
Assessment of response criteria according to RESIST, Lugano or mSWAT. |
18 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Adverse events
Délai: 24 months
|
Type, frequency, and severity of adverse drug reactions |
24 months
|
|
AUC
Délai: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Cmax
Délai: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Tmax
Délai: 6 months
|
THT140 plasma concentrations |
6 months
|
|
T1/2
Délai: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Disease Control Rate
Délai: 24 months
|
To evaluate the disease control rate (DCR) in subjects receiving THT140. |
24 months
|
|
Duration of Response
Délai: 24 months
|
To evaluate the duration of response (DOR) in subjects receiving THT140. |
24 months
|
|
Progression-free Survival
Délai: 24 months
|
To evaluate progression-free survival (PFS) in subjects receiving THT140. |
24 months
|
|
Overall Survival
Délai: 24 months
|
To evaluate overall survival (OS) in subjects receiving THT140. |
24 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pharmacodynamics
Délai: 6 months
|
Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline. |
6 months
|
|
Pharmacogenomics
Délai: 24 months
|
Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140. Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed. |
24 months
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- THT140-101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .